HHS Public Access Author manuscript Author Manuscript
Aliment Pharmacol Ther. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Aliment Pharmacol Ther. 2016 October ; 44(8): 890–898. doi:10.1111/apt.13777.
DISTAL MEAN NOCTURNAL BASELINE IMPEDANCE (MNBI) ON pH-IMPEDANCE MONITORING PREDICTS REFLUX BURDEN AND SYMPTOMATIC OUTCOME IN GASTROESOPHAGEAL REFLUX DISEASE
Author Manuscript
Amit Patel, MD, Dan Wang, MD, Nitin Sainani, MD, Gregory S. Sayuk, MD, MPH, and C. Prakash Gyawali, MD, MRCP Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri
Abstract Background—Mean nocturnal baseline impedance (MNBI), a novel pH-impedance metric, may be a surrogate marker of reflux burden. Aim—To assess the predictive value of MNBI on symptomatic outcomes after antireflux therapy.
Author Manuscript
Methods—In this prospective observational cohort study, pH-impedance studies performed over a 5-year period were reviewed. Baseline impedance was extracted from 6 channels at three stable nocturnal 10-min time periods, and averaged to yield MNBI. Distal and proximal esophageal MNBI values were calculated by averaging MNBI values at 3, 5, 7, and 9 cm, and 15 and 17 cm, respectively. Symptomatic outcomes were measured as changes in global symptom severity (GSS, rated on 100-mm visual analog scales) on prospective follow-up after medical or surgical antireflux therapy. Univariate and multivariate analyses assessed the predictive value of MNBI on symptomatic outcomes.
Author Manuscript
Results—Of 266 patients, 135 (50.8%) were tested off PPI therapy and formed the study cohort (52.1±1.1 yrs, 63.7% F). The 59 with elevated acid exposure time (AET) had lower composite and distal MNBI values than those with physiologic AET (p
Aliment Pharmacol Ther. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Aliment Pharmacol Ther. 2016 October ; 44(8): 890–898. doi:10.1111/apt.13777.
DISTAL MEAN NOCTURNAL BASELINE IMPEDANCE (MNBI) ON pH-IMPEDANCE MONITORING PREDICTS REFLUX BURDEN AND SYMPTOMATIC OUTCOME IN GASTROESOPHAGEAL REFLUX DISEASE
Author Manuscript
Amit Patel, MD, Dan Wang, MD, Nitin Sainani, MD, Gregory S. Sayuk, MD, MPH, and C. Prakash Gyawali, MD, MRCP Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri
Abstract Background—Mean nocturnal baseline impedance (MNBI), a novel pH-impedance metric, may be a surrogate marker of reflux burden. Aim—To assess the predictive value of MNBI on symptomatic outcomes after antireflux therapy.
Author Manuscript
Methods—In this prospective observational cohort study, pH-impedance studies performed over a 5-year period were reviewed. Baseline impedance was extracted from 6 channels at three stable nocturnal 10-min time periods, and averaged to yield MNBI. Distal and proximal esophageal MNBI values were calculated by averaging MNBI values at 3, 5, 7, and 9 cm, and 15 and 17 cm, respectively. Symptomatic outcomes were measured as changes in global symptom severity (GSS, rated on 100-mm visual analog scales) on prospective follow-up after medical or surgical antireflux therapy. Univariate and multivariate analyses assessed the predictive value of MNBI on symptomatic outcomes.
Author Manuscript
Results—Of 266 patients, 135 (50.8%) were tested off PPI therapy and formed the study cohort (52.1±1.1 yrs, 63.7% F). The 59 with elevated acid exposure time (AET) had lower composite and distal MNBI values than those with physiologic AET (p
